Alzheimer's disease
Lilly Alzheimer drug faces more delays as FDA plans hearing
Eli Lilly’s Alzheimer’s disease drug donanemab faces further delays in gaining approval, with US regulators planning to hold a hearing of external advisers to explore how safe the therapy is and how w...
Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More
